Objective: In postmenopausal women, a relationship between luteinizing hormone (LH) and cortisol levels has been suggested. Furthermore, LH receptors in the adrenal gland have been shown to mediate adrenocorticotropic hormoneYindependent Cushing syndrome. In contrast, follicle-stimulating hormone (FSH) receptors have not been found in the adrenal gland. Our objective was to explore the relationship of LH with adrenal function in postmenopausal women, as assessed by 24-hour urinary free cortisol (UFC) and aldosterone excretion rate (AER).
M enopause heralds change in women's health, with increased incidence of metabolic syndrome 1 and cardiovascular disease (CVD). 2 Loss of estrogen has been postulated to result in increased CVD risk. However, the rise of gonadotropins is characteristic of menopause and may play a role in CVD risk, independent of loss of estrogen.
Luteinizing hormone (LH) receptors have been identified in the adrenal gland, and case reports have described LH-mediated, adrenocorticotropic hormone (ACTH)Yindependent Cushing syndrome in postmenopausal women. 3<5 Serum cortisol increases with age in both men and women, and levels are higher in postmenopausal women than in age-matched men. 6 A few case reports 3<5 and one previous study 7 have also sug-gested a relationship between LH and serum cortisol in postmenopausal women.
The literature indicates that measurements of 24-hour urinary free cortisol (UFC) and aldosterone excretion rates (AER) are superior to isolated serum measurements of cortisol and aldosterone in providing integrated assessment of cortisol and aldosterone secretion over a 24-hour period. 8, 9 With this study, we explore the relationship of LH with UFC and AER in postmenopausal women.
METHODS

Study population
Thirty-eight normotensive and hypertensive postmenopausal women studied by the International Hypertensive Pathotype group were selected for this analysis. 10 Women were selected for this analysis if they had confirmed postmenopause status, defined as amenorrhea for at least 12 consecutive months and a follicle-stimulating hormone (FSH) level higher than 30 IU/L. Normotensive women had systolic blood pressure lower than 140 mm Hg and diastolic blood pressure lower than 90 mm Hg at both screening and study visits. For hypertensive women, diagnosis was confirmed by review of medical records or by elevated blood pressure at the screening visit. No participants were taking prescription medications, including antihypertensive medications, or hormone therapy at the time of study. For women who had previously taken hormone therapy, at least 3 months had elapsed between use of hormone therapy and study visit. Study participants did not have any active medical issues, including diabetes mellitus. Because a previous study suggested a bimodal distribution of association between LH and cortisol, with a lack of association with an LH greater than 41 mIU/mL, 7 we restricted analyses to women who had an LH level lower than 41 mIU/mL. This restriction removed only two women from our data set.
Study protocol
Participants were admitted to the Clinical Research Center of Brigham and Women's Hospital. After the women fasted and remained supine overnight, blood was drawn between 7 and 8 AM for measurement of LH, FSH, cortisol, aldosterone, plasma renin activity (PRA), and angiotensin II (Ang II). To decrease variability in endogenous PRA and Ang II, all participants ingested a standardized isocaloric high-salt diet containing 250 mEq of sodium for 1 week before the study. Sodium balance was confirmed by a 24-hour urinary sodium excretion of 200 mmol or greater. Twenty-four hour urine collection was performed for determination of UFC and urinary AER. Urinary creatinine confirmed complete urine collection. All participants provided a written informed consent form, and the institutional review board at Brigham and Women's Hospital approved the study protocol.
Laboratory assays
Blood samples were collected on ice and centrifuged in a refrigerated centrifuge. Serum LH, FSH, cortisol, estradiol, and progesterone were measured using paramagnetic-particle chemiluminescence immunoassays (Access Chemiluminscent Immunoassay, Beckman Coulter, Fullerton, CA). Serum aldosterone, UFC, and AER were measured using a Coat-A-Count Extraction radioimmunoassay (Siemens, Los Angeles, CA). The reference range for UFC is 21 to 85 Kg/24 hours. In high sodium balance, the reference range for AER is up to 6 Kg/ 24 hours, and that for an ad libitum sodium diet is up to 25 Kg/ 24 hours. PRA was measured using radioimmunoassay (Diosorin, Inc., Stillwater, MN), and Ang II levels were measured using double-antibody radioimmunoassay (ALPCO Diagnostics, Salem, NH). Urinary sodium and creatinine were measured using autoanalyzers. The analytical sensitivity for LH was 0.2 mIU/ mL, with a precision of 4.3% to 6.4%. The analytical sensitivity and precision for FSH were 0.2 mIU/mL and 3.1% to 4.3%. The analytical sensitivity and precision for cortisol were 0.4 Kg/dL and 4.4%. The analytical sensitivity and precision for aldosterone were 2.5 ng/dL and 2.5%. The analytical sensitivity and precision for estradiol were 20 pg/mL and 12%. The analytical sensitivity and precision for progesterone were 0.08 ng/mL and 6.1%. The analytical sensitivity for AER and UFC was 0.1 ng/dL and 0.2 Kg/dL, respectively. The intra-assay variations for AER and UFC were 2.3% to 5.4% and 3.0% to 4.8%, respectively. The analytical sensitivity and precision for PRA were 0.1 ng mL j1 hour j1 and 4.6%. The analytical sensitivity and precision for Ang II were 0.6 pg/mL and 7.1%.
Statistical analysis
The Shapiro-Wilk test was used to test for normal distribution. Nonnormally distributed data were log-transformed for correlation. Comparisons of LH and FSH levels to levels of cortisol, aldosterone, UFC, and AER were performed individually by calculation of Pearson's correlation coefficient. Multivariate linear regression models were used to examine the effect of LH and covariates on outcome variable. Best-fit lines were obtained using the least-squares method. For normally distributed data, the independent t test was used for two-group comparisons of demographic characteristics and hormone levels between normotensive and hypertensive subgroups. For nonnormally distributed data, the Wilcoxon rank sum test was used. Data are expressed as mean T SD. A P value of less than 0.05 was significant. Analyses were performed using JMP version 9.0.0 (SAS Institute, Inc. Cary, NC).
RESULTS
Eighteen women were normotensive at the time of study, and 18 women were hypertensive (Table 1) . A majority of women were white and overweight. All women completed menopause at least 12 months before the study, and serum levels of LH and FSH were in the menopausal range. Estradiol and progesterone levels also were in the menopausal range, with all women having serum estradiol less than 25 pg/mL and serum progesterone less than 1.4 ng/mL. Urinary sodium excretion confirmed sodium balance (Table 1 ). In sodium balance (250 mEq sodium/d), serum aldosterone and urinary AER were appropriately low. Serum cortisol and UFC were in the reference range.
There was a significant direct correlation of serum LH with log UFC (Fig. 1 ). In addition, there was a significant inverse correlation between serum LH and log AER (Fig. 1) . No correlation was found between LH and log serum cortisol or log serum aldosterone, nor were there correlations of FSH with log UFC, log AER, log cortisol, or log aldosterone. Multivariate linear regression models showed that LH independently predicted levels of log UFC (A = 0.01; SE, 0.005; 95% CI, 0.002-0.02; P = j0.017), after inclusion of age, years from menopause, and body mass index (BMI). In addition, LH independently predicted log AER (A= j0.02; SE, 0.007; 95% CI, j0.04 to j0.009; P = j0.003).
When comparing the normotensive group with the hypertensive subgroup, there were no significant differences in age, racial distribution, years from menopause, LH, FSH, UFC, or urinary sodium excretion. Although both subgroups of women were overweight by BMI, women with hypertension did have a slightly higher BMI (Table 1 ). In addition, hypertensive women had significantly higher urinary AER. In normotensive women, LH was positively correlated with log UFC (r = 0.64, P = 0.004) and negatively correlated with log AER (r = j0.59, P = 0.008). In addition, in hypertensive women, LH was negatively correlated with log AER (r = j0.54, P = 0.02) but was not significantly correlated with log UFC (r = 0.17).
There were no significant correlations of age, BMI, years from menopause, estradiol, or progesterone with cortisol, aldosterone, UFC, or AER in the whole study population or in the subgroups.
DISCUSSION
We found that serum LH correlates positively with UFC and negatively with AER in postmenopausal women, inde-pendent of age, BMI, and time from menopause. In contrast, no correlations were observed with FSH and UFC or AER. These data provide evidence that postmenopausal elevations in LH may affect adrenal function and favor cortisol secretion over aldosterone secretion.
A correlation of LH with adrenocortical function in our study population was present for UFC and AER, but not for serum cortisol and aldosterone. Measurements of UFC and AER provide integrated assessment of cortisol and aldosterone secretion over a 24-hour period and are superior to single serum measurements of cortisol and aldosterone in diagnosing cortisol or aldosterone excess. 8, 9 Our study was able to detect a relationship of LH with cortisol and aldosterone excretion that was not captured by single serum cortisol or aldosterone measurements. It is possible that a parallel relationship would be seen with serum levels with larger sample size.
LH may modulate adrenal function directly by binding to adrenal LH receptors or indirectly by increasing ACTH levels. Adrenal cortex and gonadal cells have a similar origin, originating from urogenital ridge cells. 11 Ambiguity of adrenal and gonadal gene expression occurs during the fetal period 12 and may return in the presence of high gonadotropin levels. 13<15 The fetal adrenal zone is located interior to zones that develop into adrenal cortex and atrophies after birth. 16 A postmortem study examined adrenal glands from men and women and discovered that the deeper layer of the zona fasciculata and all of the reticularis contained LH receptor protein and transcripts, identified by in situ hybridization and immunocytochemistry. 17 LH receptor proteins have also been identified in adrenal glands in cases of ACTH-independent Cushing syndrome. 4, 5, 18 Although LH receptors have been identified in aldosterone-producing adenomas, 19, 20 they have not been found in the zona glomerulosa of patients without adrenal pathology. 17 This evidence suggests that LH may act directly by binding to adrenal LH receptors to favor cortisol secretion in patients without overt adrenal pathology.
However, LH may increase ACTH levels and increase cortisol levels indirectly, via ACTH action on adrenal cortex. In a clinical study involving normal women receiving LH injections, parallel increases in ACTH and cortisol were observed. 3 Suppression of ACTH by dexamethasone prevented the increase in cortisol observed after LH injection, 3 supporting mediation of LH's effects on the adrenal gland by a rise in ACTH. Furthermore, another study showed that with ACTH stimulation, LH-releasing hormone does not augment glucocorticoid secretion, suggesting a common mechanism of stimulation. 18 Our analyses show that LH is directly correlated with UFC but inversely correlated with AER. The relationship of LH with UFC and AER levels is similar to the observed relationship of ACTH with cortisol and aldosterone secretion in clinical studies. 21, 22 In these studies, elevated levels of ACTH, achieved by infusion of ACTH, resulted in increased serum cortisol levels but decreased serum aldosterone levels. 22 Similarly, in vitro studies have demonstrated that continued daily pulsations of ACTH result in a rise in cortisol secretion but decreased aldosterone secretion. 23 Based on these findings, it is possible that LH has a similar effect to ACTH on adrenal function, or that LH action on the adrenal is mediated via ACTH.
Our study has several strengths. Women were healthy and studied in a research setting without interfering medications, including antihypertensive medications. In addition, participants were fed a standardized salt diet, removing possible confounding caused by variable endogenous PRA and Ang II levels. In addition, the urinary assays provided integrated measures of cortisol and aldosterone secretion and assisted in detecting low levels of aldosterone in high sodium balance. The relationship of LH with AER is further strengthened, as it was observed separately in normotensive and hypertensive subgroups.
There were several limitations to our study. Findings would have been bolstered by measurement of ACTH levels, which were not collected at the time of study. Our sample size was smaller than that of a previously published study, 7 which may have limited our ability to detect correlations of LH with serum cortisol or aldosterone levels or to determine if the relationship differs between normotensive and hypertensive populations. However, our analyses indicate that the relationship of LH with urinary markers of adrenal function is strong and significant. Further studies need to be done to fully characterize this association and its possible implications for postmenopausal women.
CONCLUSIONS
In summary, we demonstrate that in a population of postmenopausal women, both normotensive and hypertensive, serum LH correlates positively with UFC and negatively with AER, independent of age, BMI, and time from menopause. No relationship was detected with serum FSH. Our findings suggest that elevated levels of LH effect subtle changes in adrenal function in postmenopausal women to favor cortisol secretion over aldosterone secretion. Furthermore, these changes in adrenal function may contribute to the increased incidence of metabolic syndrome and CVD observed in women after menopause.
